Introduction {#S1}
============

Alzheimer's disease (AD) is the most common neurodegenerative disorder in the world, in which pathological characteristics include the extracellular accumulation of senile plaques containing amyloid-β (Aβ) deposits, and neurofibrillary tangles containing hyper-phosphorylated tau ([@B1], [@B2]). Autophagy is a highly conserved intracellular pathway involved in the organized elimination of proteins and organelles by lysosomes, which are recently reported to be important for neuronal survival and AD pathogenesis in several studies ([@B3]--[@B5]). Particularly, during autophagy, lysosomes fuse with autophagosomes to form autolysosomes. Following starvation-induced autophagy, nascent lysosomes are formed from autolysosomal membranes through an evolutionarily conserved cellular process, called autophagic lysosome reformation (ALR) that is critical for maintaining lysosome homeostasis ([@B6]). Since autophagy is strongly associated with AD pathogenesis, along with the fact that ALR is critical for maintaining lysosome homeostasis, it seems that ALR is also participate in the AD progression.

Transient receptor potential mucolipin-1 (TRPML1) is widely expressed in mammalian cells in the lysosomes or endosome membrane ([@B7]), and is the main channel of lysosome Ca^2+^ release and the key regulator for lysosomal storage and transportation ([@B8]). Besides, TRPML1 is considered to be the regulator of autophagy and intraneuronal accumulation of Aβ ([@B7], [@B9]). Importantly, this study indicated that TRPML1 functions as an endolysosomal Ca^2+^ release channel that is regulated by PI(3,5)P2 ([@B10]). PI(3,5)P2 is a low-abundance endolysosome-specific phosphoinositide (PIP) and can be generated from PI(3)P through a PI 5 kinase, called PIKfyve/Fab1, which is localized in the endolysosome of both yeast and mammalian cells ([@B11]). These investigations indicate that PI(3,5)P2 may participate in the pathogenesis of AD by regulating TRPML1, which induced the alteration in the endolysosomal Ca^2+^ release channel and caused autophagy--lysosome dysfunction, which finally affects the pathogenesis of AD.

Curcumin, a major polyphenol from curry spice (*Curcuma longa*), has been reported to inhibit Aβ aggregation, Aβ-induced inflammation, and the activities of β-secretase and acetylcholinesterase in *in vitro* studies ([@B12], [@B13]). Moreover, in *in vivo* studies, oral administration of curcumin has resulted in the inhibition of Aβ oligomerization, Aβ deposition, and tau phosphorylation in the brains of AD animal models, as well as led to the improvements in behavioral impairment in animal models ([@B12]). In our previous study, we found that chronic curcumin administration ameliorates Aβ1-42 induced AD-related cognitive deficits ([@B13]). However, more information underlying the mechanism should be explored.

Based on these research results, we speculated that curcumin may ameliorate AD pathogenesis by regulating PI(3,5)P2 and TRPML1 expression levels. To validate it, we first detect the effects of curcumin on lysosomes and the cell viability of hippocampal HT-22 cells that treated with Aβ1-42. Sequencing technique was then used and TRPML1 was identified as the most upregulated gene that affected by curcumin. Afterward, the effects of curcumin on the autophagy-related proteins were also analyzed *in vitro*. Besides, we also determined that curcumin ameliorated autophagy--lysosome dysfunction by regulating PI(3,5)P2 and TRPML1 *in vivo*. Our study suggests that curcumin might be one of the most promising compounds for the interference of AD therapies.

Materials and Methods {#S2}
=====================

Animals {#S2-1}
-------

A total of 50 male and female AβPPswe/PSEN1dE9 (AβPP/PS1) transgenic mice were used. The double-transgenic (Tg) mice were obtained from Jackson Laboratory \[strain name B6C3-Tg (AβPPswe, PSEN1dE9) 85Dbo/J; stock number 004462\]. These B6C3-based Tg mice harbor two AD-related genes, one encoding a chimeric mouse/human Aβ protein precursor containing the K595N/M596L Swedish mutation (Aβ PPswe) and the other a mutant human presenilin 1 carrying a deletion of exon 9 (PSEN1dE9). APPSwe is the Swedish mutation of the amyloid precursor protein, and PS1 is the mutant form of human presenilin 1 ([@B14]). The mice were genotyped from tail tissue as previously described ([@B15]). Since early onset memory decline was induced in the Tg mice at 6 months, as reported previously ([@B16]), mice at this age was used. Mice were divided into five groups (*n* = 10 in each group): the control group, mice treated with curcumin, mice treated with curcumin and with *in vivo* sh-TRMPL1 transfection, and mice treated with curcumin and with *in vivo* sh-PI(3,5)P2 transfection. Animals were maintained at room temperature (25 ± 2°C) under a controlled environment (12 h-light/12 h-dark cycle), with free access to water and food. Curcumin were administrated orally (200 mg/kg) in APP/PS1 transgenic mice for 3 month. The concentration was decided by our previous study ([@B13]). Mice were enrolled for the Morris water maze (MWM) test and hippocampus tissue was obtained 24 h later for Western blotting analysis. The protocol was approved by the Ethics Committee of the Animal Experiments of the University of Zhengzhou.

Amyloid-β1-42 (Aβ1-42) Preparation and Cell Culture {#S2-2}
---------------------------------------------------

Curcumin (\~80% pure) and Aβ1-42 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Aβ1-42 preparation was performed as previously described ([@B17]). In brief, peptides were reconstituted in sterile water at a concentration of 400 mM. Aliquots of stocks were incubated at 37°C for 3 days to form aggregated amyloid. A final concentration of 10 μM was used in our study. Curcumin preparation was performed as previously described ([@B18]). In brief, the stock curcumin were dissolved in methanol and then diluted in the DMEM or MEM (methanol was \<1%), before being added to the Petri dish containing the cells. The mouse clonal hippocampal neuronal cell line HT-22 were maintained at 37°C and 5% CO~2~ in complete medium containing DMEM high glucose supplemented with 10% heat-inactivated fetal bovine serum, 50 mg/mL streptomycin, 50 U/mL penicillin, and passed by tripsinization. Aβ1-42-treated HT-22 cells were treated with a single dose of curcumin (0, 5, 10, and 15 μM) for 24 or 48 h.

Illumina RNA-seq {#S2-3}
----------------

RNA samples were used for the preparation of cDNA libraries by using an mRNA-seq Sample Preparation Kit (Illumina, San Diego, CA, USA) as previously described ([@B19]). Briefly, double-stranded cDNA was prepared and reverse transcribed. The double-stranded cDNA was ligated and the ligated DNA was amplified before library assessment and quantitation. Cluster generation of loads of a single mRNA-seq library per lane was performed on the Cluster Station. Sequence-by-synthesis single reads of 54 base length using the SBS Sequencing Kit v4 (Illumina) were generated on the Genome Analyzer IIx.

Knockdown of PI(3,5)P2 or TRPML1 in HT-22 Cells or in APP/PS1 Transgenic Mice {#S2-4}
-----------------------------------------------------------------------------

The sequences of PI(3,5)P2 and TRPML1 were cloned by PCR and the generation of the PI(3,5)P2 or TRPML1 shRNA was constructed. The primer for TRPML1 was 5′-CCCACATCCAGGAGTGTAA-3′. The recombinant lentivirus eukaryotic expression plasmids Lenti-TRPML1-shRNA and Lenti-PI(3,5)P2-shRNA were constructed. After sequencing, the lentivirus vectors were transfected into 293T cells. The supernatant was collected and the viral particles were concentrated and HT-22 cells were infected. APP/PS1 transgenic mice were injected with viral particles as described in our previous study ([@B13]). The transfection efficiency was detected by Western blotting 24 h after knockdown of PI(3,5)P2 or TRPML1 in HT-22 cells and then exposed to curcumin for 48 h.

MTS Assay {#S2-5}
---------

Cell viability was measured by the cellular ability to metabolize MTS (Promega) in the presence of phenazine methosulfate to a formazan product, as described previously ([@B20]). The absorbance value at 490 nm was measured to calculate cell viability. The results were shown as the percentage of the control group.

Lysosomal Ca^2+^ Measurements {#S2-6}
-----------------------------

The cells in each group were washed three times with PBS, and the intracellular lysosome was extracted by lysosome extraction kit (Sigma-Aldrich, St. Louis, MO, USA). Then, 3 µmol/L Fluo-3AM solution was immediately added, and incubated in a incubator at 37°C for 30 min. After aspirating the working fluid, lysosome was rinsed with PBS for three times, and PBS was added to balance for 10 min, and finally for observation. By using Ca^2+^ analyzer, the image and time was obtained with real-time monitoring *via* NIS-Element AR3.0 (Nikon) software system, with a period of 6 min. Lysosomal Ca^2+^ intensity was expressed as R340/380 (Wavelengths at 340 and 380 nm, respectively). Each experiment was detected at least 10 cells, baseline was also detected (baseline fluctuates within a relatively small range), with each experiment repeating at least three times.

Transmission Electron Microscopic Examination {#S2-7}
---------------------------------------------

The transmission electron microscopic examination was performed to assess the autophagosome formation. Briefly, cells were digested with trypsin, centrifuged, and washed. Then, the samples were fixed with 2.5% glutaraldehyde and 2% osmium acid for 2 h; and then dehydrated by ethanol gradient and embedded with anhydrous acetone/embedding solution (2:1). The embedding plate was then placed at 65°C for more than 48 h after polymerization. The sample was cut and the sample surface area is less than 0.2 mm × 0.2 mm, and then sliced into a thickness of 70 nm. Finally, the sample was stained with uranium and plumbum for 5--15 min, respectively. After washing, the sample was imaged.

Western Blot Analysis {#S2-8}
---------------------

For Western blot analysis, cell lysates were prepared from cell line or hippocampus tissue with RIPA lysis buffer kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and the protein concentrations were quantified using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Whole-cell proteins (30 µg) were separated on 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Amersham Corp., Arlington Heights, IL, USA). The membranes were incubated with primary antibodies (anti-TRPML1, -mTOR, -p-mTOR, -S6K, -p-S6K, -Beclin-1, -LC3-I, -LAMP-1, or -β-actin, all obtained from Abcam, Cambridge, MA, USA) overnight at 4°C. Secondary antibodies were subsequently used. Signals were detected using ECL and exposed to Kodak X-OMAT film (Eastman Kodak, Rochester, NY, USA). The results were scanned and analyzed using Alpha View Analysis Tools.

The MWM Test {#S2-9}
------------

After knockdown of PI(3,5)P2 or TRPML1 in APP/PS1 transgenic mice, curcumin were administrated orally (200 mg/kg) in APP/PS1 transgenic mice for 3 months. The MWM test was performed to evaluate the escape latency (the time to reach the hidden platform), traveled distance (the length of swim path), and times across platform of mice (at age of about 9 month) as described in previous studies ([@B21], [@B22]). Recognition task was preformed as described previously ([@B23]).

Statistical Analyses {#S2-10}
--------------------

Data were presented as the mean ± SEM and analyzed by using SPSS18.0. Each experiment was performed at least three times. Comparisons among multiple groups were analyzed by 1- or 2-way analysis of variance followed by Fischer protected least significant difference *post hoc* tests. Comparisons between two groups were analyzed by Student's 2-tailed unpaired *t*-test. The significance differences were indicated as a *p*--value \<0.05.

Results {#S3}
=======

Curcumin Increased Cell Viability, Decreased the Number of Autophagosomes, and Increased Lysosomal Ca^2+^ Levels in Aβ1-42-Treated HT-22 Cells {#S3-1}
----------------------------------------------------------------------------------------------------------------------------------------------

First, Aβ1-42-treated HT-22 cells were treated with a single dose of curcumin (0, 5, 10, and 15 μM) and the cell viability was detected at 24 and 48 h. The results revealed that curcumin significantly increased cell viability, with the maximum cell viability was observed at a concentration of 10 μM (Figure [1](#F1){ref-type="fig"}A). The results of transmission electron microscopic examination showed that curcumin decreased the number of autophagosomes in Aβ1-42-treated HT-22 cells (Figure [1](#F1){ref-type="fig"}B). Besides, we found that curcumin significantly increased lysosomal Ca^2+^ levels and the highest level was observed at a concentration of 10 μM (Figure [1](#F1){ref-type="fig"}C). These results indicated the effects of curcumin on neuronal cell growth and autophagy.

![Curcumin increased the cell viability, decreased the number of autophagosomes, and increased lysosomal Ca^2+^ levels in amyloid-β1-42 (Aβ1-42)-treated HT-22 cells. **(A)** Curcumin significantly increased cell viability, with the maximum cell viability was observed at a concentration of 10 μM. **(B)** The results of transmission electron microscopic examination showed that curcumin decreased the number of autophagosomes in Aβ1-42-treated HT-22 cells. **(C)** Curcumin significantly increased lysosomal Ca^2+^ levels and the highest level was observed at a concentration of 10 μM. ^\#^*p* \< 0.05 compared to the Aβ1-42 control.](fneur-08-00531-g001){#F1}

TRPML1 Was the Most Upregulated Gene after Curcumin Use in Aβ1-42-Treated HT-22 Cells {#S3-2}
-------------------------------------------------------------------------------------

Sequencing analysis was performed to analyze the different expression patterns between Aβ1-42-treated HT-22 cells without and with 10 μM curcumin treatment groups after 48 h. A total of 15 significant probe sets were identified to have \>2-fold change between two groups. Indeed, TRPLML1 was identified as the most significantly upregulated gene after curcumin treatment (Table [1](#T1){ref-type="table"}).

###### 

The upregulated gene (\>2-folds) after curcumin use in Aβ1-42-treated HT-22 cells.

  Upregulated genes   Fold change   False discovery rate   *p*-Value
  ------------------- ------------- ---------------------- -------------
  Olfm2               2.008199131   0.307749759            0.015073129
  Rp112-ps1           2.00944032    0.41860459             0.047665884
  Serpinb8            2.018891221   0.39244849             0.038288911
  Nhej1               2.019885894   0.354055378            0.026982349
  Fstl3               2.022499151   0.309592995            0.015280283
  Mbnl2               2.024160488   0.203199802            0.001609951
  Sat1                2.031986672   0.321217899            0.017100551
  Eva1b               2.034394      0.4026600235           0.041732931
  Ppp1r2-ps3          2.046274941   0.282211392            0.00978792
  Phf13               2.053599077   0.264746112            0.00713521
  RP23-184B11.2       2.06755355    0.322441797            0.017815296
  Hsdl2               2.071794815   0.339514124            0.022942547
  Car14               2.07861076    0.334696636            0.020181275
  Sf3b2               2.081406505   0.231346295            0.003572899
  Nsun3               2.088071251   0.396321681            0.039843913
  Mgst2               2.088701265   0.251662663            0.00506601
  Trpml1              2.099670809   0.30640473             0.045523332

TRPML1 Was Upregulated, mTOR/S6K Signaling Pathway Was Activated, and the Markers of the Autophagy--Lysosomal System Were Downregulated after Curcumin Use in Aβ1-42-Treated HT-22 Cells {#S3-3}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Then, we performed the Western blotting to validate the results by the sequencing analysis. The protein level of TRPML1 was downregulated after Aβ1-42 treatment as compared to the control. However, curcumin use (10 μM) upregulated the protein level of TRPML1 in Aβ1-42-treated HT-22 cells(Figure [2](#F2){ref-type="fig"}A).

![Transient receptor potential mucolipin-1 (TRPML1) was upregulated, mTOR/S6K signaling pathway was activated, and markers of the autophagy--lysosomal system were downregulated after curcumin use in amyloid-β1-42 (Aβ1-42)-treated HT-22 cells. **(A)** The protein level of TRPML1 was downregulated after Aβ1-42 treatment as compared to the control, curcumin reversed this result. **(B)** Curcumin use upregulated Aβ1-42-inhibited protein levels of p-mTOR and p-S6K. **(C)** Curcumin use downregulated Aβ1-42-induced protein levels of Beclin, LC3, and LAMP-1. \**p* \< 0.05 compared to the control group and ^\#^*p* \< 0.05 compared to the Aβ1-42 group.](fneur-08-00531-g002){#F2}

Since TRPML1 was strongly associated with autophagy, autophagy-related signaling pathway, and proteins were also detected. The mTOR/p70 ribosomal protein S6 kinase (p70S6K, S6K) signaling pathway is accepted to negatively regulate autophagy in mammalian cells, and Beclin, LC3, and LAMP-1 are markers of the autophagy--lysosomal system ([@B24], [@B25]). Here, we found the protein levels of p-mTOR and p-S6K were downregulated, and Beclin, LC3, and LAMP-1 were upregulated after Aβ1-42 treatment as compared to the control. However, curcumin use reversed these protein levels in Aβ1-42-treated HT-22 cells (Figures [2](#F2){ref-type="fig"}B,C).

Knockdown of PI(3,5)P2 or TRPML1 Increased the Protein Levels of Markers of the Autophagy--Lysosomal System after Curcumin Use in Aβ1-42-Treated HT-22 Cells {#S3-4}
------------------------------------------------------------------------------------------------------------------------------------------------------------

PI(3,5)P2 or TRPML1 was knocked down in Aβ1-42-treated HT-22 cells respectively, and were then exposed to curcumin, and the transfection efficiency was determined (Figures [3](#F3){ref-type="fig"}A,B). After knockdown of PI(3,5)P2 or TRPML1 after curcumin use (10 μM) in Aβ1-42-treated HT-22 cells, we found that the protein levels of Beclin, LC3, and LAMP-1 were increased as compared to the Aβ1-42-treated HT-22 cells with curcumin usage, which were comparable to the expression levels in Aβ1-42-treated HT-22 cells (Figures [3](#F3){ref-type="fig"}C--E). To some extent, it suggested that the effects of curcumin on the protein levels of Beclin, LC3 and LAMP-1 can be eliminated by PI(3,5)P2 or TRPML1 knockdown *in vitro*.

![Knockdown of PI(3,5)P2 or transient receptor potential mucolipin-1 (TRPML1) significantly increased the protein levels of markers of the autophagy--lysosomal system after curcumin use in amyloid-β1-42 (Aβ1-42)-treated HT-22 cells. **(A)** PI(3,5)P2 was knocked down in Aβ1-42-treated HT-22 cells, and were then exposed to curcumin, and the transfection efficiency was determined. **(B)**TRPML1 was knocked down in Aβ1-42-treated HT-22 cells, and were then exposed to curcumin, and the transfection efficiency was determined. Knockdown of PI(3,5)P2 or TRPML1 significantly increased the protein levels of Beclin **(C)**, LC3 **(D)**, and LAMP-1 **(E)** after curcumin use in Aβ1-42-treated HT-22 cells as compared to the Aβ1-42-treated HT-22 cells with curcumin usage, which were comparable to the expression levels of the Aβ1-42-treated HT-22 cells. \**p* \< 0.05 compared to the control group, ^\#^*p* \< 0.05 compared to the Aβ1-42 group, and ^&^*p* \< 0.05 compared to the Aβ1-42 + CUR group.](fneur-08-00531-g003){#F3}

Knockdown of PI(3,5)P2 or TRPML1 Inhibited mTOR/S6K Signaling Pathway and Increased the Protein Levels of Markers of the Autophagy--Lysosomal System after Curcumin Use in APP/PS1 Mice {#S3-5}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Furthermore, we want to validate the involvement of PI(3,5)P2 or TRPML1 in the effects of curcumin on the pathogenesis of AD, APP/PS1 transgenic mice were used. As shown in Figure [4](#F4){ref-type="fig"}, the results showed that the protein level of TRPML1 was significantly downregulated, and the protein levels of p-mTOR and p-S6K were downregulated, and Beclin, LC3, and LAMP-1 were upregulated in APP/PS1 transgenic mice as compared to the control. The low levels of TRPML1 p-mTOR and p-S6K, and high levels of Beclin, LC3, and LAMP-1 were abrogated following curcumin treatment (200 mg/kg). We also found that the protein level of TRPML1 in APP/PS1 + CUR + Sh-TRPML1 group was decreased, and PI(3,5)P2 knockdown in APP/PS1 transgenic mice with curcumin treatment decreased the protein level of TRPML1 as compared to the APP/PS1 + CUR group. Importantly, knockdown of PI(3,5)P2 or TRPML1 decreased the protein levels of p-mTOR, p-S6K, but increased Beclin, LC3, and LAMP-1 protein levels after curcumin use in APP/PS1 mice. It also proved that the effects of curcumin on the protein levels of Beclin, LC3, and LAMP-1 can be eliminated by PI(3,5)P2 or TRPML1 knockdown *in vivo*.

![Knockdown of PI(3,5)P2 or transient receptor potential mucolipin-1 (TRPML1) inhibited mTOR/S6K signaling pathway and increased the protein levels of markers of the autophagy--lysosomal system after curcumin use in APP/PS1 mice. **(A)** The protein level of TRPML1 in APP/PS1 + CUR + Sh-TRPML1 group was decreased, and PI(3,5)P2 knockdown in APP/PS1 transgenic mice with curcumin treatment decreased the protein level of TRPML1 as compared to the APP/PS1 + CUR group. **(B)** Knockdown of PI(3,5)P2 or TRPML1 decreased the protein levels of p-mTOR and p-S6K after curcumin use in APP/PS1 mice. **(C)** Knockdown of PI(3,5)P2 or TRPML1 increased the protein levels of Beclin, LC3, and LAMP-1 after curcumin use in APP/PS1 mice. \**p* \< 0.05 compared to the control. ^\#^*p* \< 0.05 compared to the APP/PS1 group. ^&^*p* \< 0.05 compared to the APP/PS1 + CUR group.](fneur-08-00531-g004){#F4}

Knockdown of PI(3,5)P2 or TRPML1 Reversed the Protective Role of Curcumin on Memory and Recognition Impairments in Mice with APP/PS1 Transgenes {#S3-6}
-----------------------------------------------------------------------------------------------------------------------------------------------

We then found that the presence of APP/PS1 transgenes caused significant inductions in escape latency (Figure [5](#F5){ref-type="fig"}A), travel length (Figure [5](#F5){ref-type="fig"}B), and times cross the platform (Figure [5](#F5){ref-type="fig"}C) in comparison with control. The presence of APP/PS1 transgenes caused a significant reduction recognition index in comparison with control (Figure [5](#F5){ref-type="fig"}D). Curcumin treatment (200 mg/kg) caused the significant reductions in escape latency (Figure [5](#F5){ref-type="fig"}A), travel length (Figure [5](#F5){ref-type="fig"}B), and times cross the platform (Figure [5](#F5){ref-type="fig"}C) in comparison with control, but caused a significant induction in recognition index in comparison with control (Figure [5](#F5){ref-type="fig"}D). However, the protective role of curcumin on memory and recognition impairments was significantly reversed by knockdown of PI(3,5)P2 or TRPML1.

![Knockdown of PI(3,5)P2 or transient receptor potential mucolipin-1 (TRPML1) reversed the protective role of curcumin on memory and recognition impairments in mice with APP/PS1 transgenes. Knockdown of PI(3,5)P2 or TRPML1 in mice with APP/PS1 transgenes after curcumin treatment caused significant inductions in escape latency **(A)**, travel length **(B)**, and times cross the platform **(C)**, but caused a significant reduction recognition index **(D)** in comparison with APP/PS1 + CUR group. \**p* \< 0.05 compared to the control. ^\#^*p* \< 0.05 compared to the APP/PS1 group. ^&^*p* \< 0.05 compared to the APP/PS1 + CUR group.](fneur-08-00531-g005){#F5}

Discussion {#S4}
==========

Curcumin have beneficial effects on AD including antioxidative, anti-Aβ aggregation, and inhibition of acetylcholinesterase, β-secretase, and Aβ-induced inflammation *in vitro* as well as inhibition of tau phosphorylation and Aβ oligomerization in the brain *in vivo* ([@B12], [@B18]). One of the key steps in Aβ generation is cleavage of APP by β-site APP-cleaving enzyme 1 (BACE-1) and β-secretase. Lin et al. found curcumin almost completely suppressed the up-expression of APP and BACE-1 mRNA levels ([@B26]), indicating that curcumin exerts effects on APP processing. Maiti et al. ([@B18]) suggested that curcumin or solid lipid curcumin particles treatment could increase the levels of LC3A/B-II and Beclin-1, indicating that maintenance or restoration of heat shock proteins and regulation of autophagy--lysosomal pathways by curcumin may provide a promising strategy to degrade Aβ-aggregates from neurons in the AD brain. To some extent, our study is consistent with this previous study, showing that the markers of the autophagy--lysosomal system (Beclin, LC3, and LAMP-1) were downregulated after curcumin use in Aβ1-42-treated HT-22 cells.

Autophagy is reported to be affected by the mTOR, a central cell growth regulator that integrates growth factor and nutrient signals ([@B27], [@B28]). And the mTOR/S6K signaling pathway is well-known to negatively regulate autophagy ([@B24], [@B27]). The expression of mTOR/S6K signaling pathway was activated after curcumin use in Aβ1-42-treated HT-22 cells in our study. It seems that curcumin use inhibits autophagy. Conversely, Zhang et al. ([@B29]) indicated that curcumin can protect human vascular endothelial cell, mouse cardiomyocytes, and rat kidney cells from oxidative stress damage through induction of autophagy by increasing expression of autophage proteins such as LC3 and decreasing expression of mTOR proteins.

Besides, we also found that curcumin increased lysosomal Ca^2+^ levels in Aβ1-42-treated HT-22 cells. However, the underlying mechanism was not explored in our study. Bilmen et al. ([@B30]) indicated that curcumin is known to inhibit the sarcoplasmic/endoplasmic calcium ATPase (SERCA) leading to increases in cytosolic calcium levels. Another previous work has shown that inhibition of SERCA does not increase lysosomal calcium content ([@B31]). Besides, Lee et al. ([@B32]) suggested that knockdown of TRPML1 in a familial AD model increases lysosomal calcium content and decreases cytosolic Ca^2+^. Based on our results that the expression of TRPML1 was upregulated after curcumin use in Aβ1-42-treated HT-22 cells, it seems that curcumin increased cytosolic Ca^2+^ levels in Aβ1-42-treated HT-22 cells by upregulating the expression of TRPML1.

Heather et al. suggested that altered APP processing, as observed in AD, may disrupt PI(3,5)P2 metabolism, endosomal sorting, and homeostasis since APP binding to the PIKfyve complex \[consist of PIKfvye (also known as Fab1), Vac14 (ArPIKfyve), and Figure [4](#F4){ref-type="fig"} (Sac3)\] drives formation of PI(3,5)P2 positive vesicles ([@B33]). Indeed, various neurodegenerative diseases, including Charcot--Marie--Tooth and amyotrophic lateral sclerosis disease were reported in human with mutations in PI(3,5)P 2-metabolizing enzymes and their regulators ([@B34]--[@B36]). At the cellular level, PI(3,5)P 2-deficient cells reportedly exhibit enlarged endolysosomes/vacuoles and trafficking defects in endocytic pathways ([@B34], [@B36], [@B37]). A present study indicated that PI(3,5)P2 controls endolysosomal membrane trafficking by regulating TRPML channels to change juxtaorganellar Ca^2+^ level. Particularly, TRPML1 was proved to function as an endolysosomal Ca^2+^ release channel that is regulated by PI(3,5)P2 ([@B10]).

Transient receptor potential mucolipin-1 is believed to play a role in endosomal--lysosomal biogenesis and considered to be the regulator of autophagy and intraneuronal accumulation of Aβ ([@B7], [@B9]). For example, TRPML1 mutations can not only induce the occurrence of neurodegenerative lysosomal storage disorders but also affects the accumulation of autophagy ([@B7], [@B9]). A recent study suggested that, in a triple transgenic gp120/APP/PS1 mouse, HIV coat protein gp120 inhibits the activity of TRPML1 and thereby facilitates the intraneuronal accumulation of Aβ ([@B38]). Lee et al. ([@B32]) suggested that overactivation of TRPML1 is pathogenic in familial AD, and that knockdown or inhibition of TRPML1 corrects cellular calcium homeostasis defects. Based on these results, curcumin is an effectively therapeutic treatment for AD by regulating PI(3, 5)P2 and TRPML1 expression.

This study validated this speculation. Curcumin increased the cell viability, decreased the number of autophagosomes, and increased lysosomal Ca^2+^ levels in Aβ1-42-treated HT-22 cells, indicating the important role of curcumin on neuronal cell growth and autophagy. Sequencing analysis identified TRPLML1 as the most significantly upregulated gene after curcumin treatment. Western blotting results also showed that TRPML1 was upregulated, mTOR/S6K signaling pathway was activated and markers of the autophagy--lysosomal system were downregulated after curcumin use in Aβ1-42-treated HT-22 cells. Knockdown of PI(3,5)P2 or TRPML1 increased the protein levels of markers of the autophagy--lysosomal system after curcumin use in Aβ1-42-treated HT-22 cells. Knockdown of PI(3,5)P2 or TRPML1 also inhibited mTOR/S6K signaling pathway and increased the protein levels of markers of the autophagy--lysosomal system after curcumin use in APP/PS1 mice. Besides, knockdown of PI(3,5)P2 or TRPML1 reversed the protective role of curcumin on memory and recognition impairments in mice with APP/PS1 transgenes. To some extent, it suggested that the effects of curcumin on AD pathogenesis were associated with PI(3,5)P2 and TRPML1 expression levels. Our study helps us to have a better understanding of the mechanism underlying the effects of curcumin on AD.

Ethics Statement {#S5}
================

The protocol was approved by the Ethics Committee of the Animal Experiments of the University of Zhengzhou.

Author Contributions {#S6}
====================

LZ and YF conceived and designed the study. LZ, YF, XC, Y-JL, and H-lX performed the experiments. Z-SZ and H-cZ wrote the paper. LZ, YF, XC, Y-JL, H-IX, Z-SZ, and H-cZ reviewed and edited the manuscript. All authors read and approved the manuscript.

Conflict of Interest Statement {#S7}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This research was in part supported by grants from the Zhengzhou Science & Technology Basic Research Program (No. 131PPTGG409-21).

[^1]: Edited by: Alfredo Meneses, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV), Mexico

[^2]: Reviewed by: Chuang Wang, Ningbo University, China; Maria Angela Sortino, Università degli Studi di Catania, Italy

[^3]: Specialty section: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neurology
